These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 16321724)
1. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Prince JB Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724 [TBL] [Abstract][Full Text] [Related]
2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731 [TBL] [Abstract][Full Text] [Related]
3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling RL Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941 [TBL] [Abstract][Full Text] [Related]
4. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858 [TBL] [Abstract][Full Text] [Related]
5. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
6. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649 [TBL] [Abstract][Full Text] [Related]
7. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Stein MA Am J Manag Care; 2004 Jul; 10(4 Suppl):S89-98. PubMed ID: 15352535 [TBL] [Abstract][Full Text] [Related]
9. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962 [TBL] [Abstract][Full Text] [Related]
10. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate. Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329 [TBL] [Abstract][Full Text] [Related]
11. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801 [TBL] [Abstract][Full Text] [Related]
12. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Olfson M Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538 [TBL] [Abstract][Full Text] [Related]
13. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674 [TBL] [Abstract][Full Text] [Related]
14. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D; Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409 [TBL] [Abstract][Full Text] [Related]
15. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"]. Shmueli D; Gross-Tsur V Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157 [TBL] [Abstract][Full Text] [Related]
16. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ; Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203 [TBL] [Abstract][Full Text] [Related]
17. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703 [TBL] [Abstract][Full Text] [Related]
18. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216 [TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy with atomoxetine for US children and adolescents. Bhatara VS; Aparasu RR Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]